trending Market Intelligence /marketintelligence/en/news-insights/trending/tmon4icg5balunjzmywxsw2 content esgSubNav
In This List

Tetra Bio-Pharma chronic pain therapy gets US FDA orphan drug status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Tetra Bio-Pharma chronic pain therapy gets US FDA orphan drug status

Tetra Bio-Pharma Inc. said the U.S. Food and Drug Administration granted orphan drug designation to the active ingredients of its PPP001 treatment for complex regional pain syndrome.

The orphan drug status does not extend to the actual formulation of the cannabinoid-based treatment.

Complex regional pain syndrome is a condition that affects a part of the body, usually after an injury, that is believed to be caused by damage to the peripheral and central nervous systems.

Separately, Tetra reappointed Benoit Chotard to its board.

Chotard was a director of the Canadian biopharmaceutical company from September 2016 to July 2017 and had to leave for personal reasons.